Wave Life Sciences (WVE) Return on Capital Employed (2015 - 2026)
Wave Life Sciences' (WVE) quarterly Return on Capital Employed came in at 41.9% in Q2 2026, up 3655.0% YoY from 1.12% in Q2 2025, and down 19.43% on a QoQ basis from 35.08% in Q1 2026.
Wave Life Sciences (WVE) Return on Capital Employed (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of Return on Capital Employed data on file, last reported at 41.9% in Q2 2026.
- Quarterly Return on Capital Employed rose 3655.0% year-over-year to 41.9% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 41.9% (up 3655.0% YoY) and the FY2025 annual result came in at 53.81%, up 68.0% from the prior year.
- Return on Capital Employed eased to 41.9% in Q2 2026, from 35.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 35.08% in Q1 2026 to a low of 208.6% in Q1 2023.
- A 5-year average of 101.21% and a median of 89.49% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 11408 bps — and 2024, when it jumped 12773 bps.
- Tracing WVE's Return on Capital Employed over 5 years: stood at 176.05% in 2022, then advanced by 24 bps to 133.34% in 2023, then soared by 66 bps to 45.17% in 2024, then plunged by 38 bps to 62.45% in 2025, then surged by 33 bps to 41.9% in 2026.
- The last three Return on Capital Employed figures came in at 41.9% (Q2 2026), 35.08% (Q1 2026), and 62.45% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -41.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.90% |
| Mar 31, 2026 | -35.08% |
| Dec 31, 2025 | -62.45% |
| Sep 30, 2025 | -84.46% |
| Jun 30, 2025 | -78.45% |
| Mar 31, 2025 | -53.99% |
| Dec 31, 2024 | -45.17% |
| Sep 30, 2024 | -134.64% |
| Jun 30, 2024 | -171.10% |
| Mar 31, 2024 | -80.87% |
| Dec 31, 2023 | -133.34% |
| Sep 30, 2023 | -80.78% |
| Jun 30, 2023 | -125.66% |
| Mar 31, 2023 | -208.60% |
| Dec 31, 2022 | -176.05% |
| Sep 30, 2022 | -116.61% |
| Jun 30, 2022 | -98.19% |
| Mar 31, 2022 | -94.52% |
| Dec 31, 2021 | -91.01% |
| Sep 30, 2021 | -70.55% |